91 related articles for article (PubMed ID: 16757326)
1. Sequencing analysis of BRAF mutations in human cancers.
Wooster R; Futreal AP; Stratton MR
Methods Enzymol; 2006; 407():218-24. PubMed ID: 16757326
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the BRAF gene in human cancer.
Davies H; Bignell GR; Cox C; Stephens P; Edkins S; Clegg S; Teague J; Woffendin H; Garnett MJ; Bottomley W; Davis N; Dicks E; Ewing R; Floyd Y; Gray K; Hall S; Hawes R; Hughes J; Kosmidou V; Menzies A; Mould C; Parker A; Stevens C; Watt S; Hooper S; Wilson R; Jayatilake H; Gusterson BA; Cooper C; Shipley J; Hargrave D; Pritchard-Jones K; Maitland N; Chenevix-Trench G; Riggins GJ; Bigner DD; Palmieri G; Cossu A; Flanagan A; Nicholson A; Ho JW; Leung SY; Yuen ST; Weber BL; Seigler HF; Darrow TL; Paterson H; Marais R; Marshall CJ; Wooster R; Stratton MR; Futreal PA
Nature; 2002 Jun; 417(6892):949-54. PubMed ID: 12068308
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the ARAF gene in human cancers.
Lee JW; Soung YH; Kim SY; Park WS; Nam SW; Min WS; Kim SH; Lee JY; Yoo NJ; Lee SH
APMIS; 2005 Jan; 113(1):54-7. PubMed ID: 15676015
[TBL] [Abstract][Full Text] [Related]
7. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
[TBL] [Abstract][Full Text] [Related]
9. RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
[TBL] [Abstract][Full Text] [Related]
10. B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Jaworski M; Buchmann A; Bauer P; Riess O; Schwarz M
Oncogene; 2005 Feb; 24(7):1290-5. PubMed ID: 15592514
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation testing in clinical practice.
Ziai J; Hui P
Expert Rev Mol Diagn; 2012 Mar; 12(2):127-38. PubMed ID: 22369373
[TBL] [Abstract][Full Text] [Related]
13. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.
Jarry A; Masson D; Cassagnau E; Parois S; Laboisse C; Denis MG
Mol Cell Probes; 2004 Oct; 18(5):349-52. PubMed ID: 15294323
[TBL] [Abstract][Full Text] [Related]
14. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
Emuss V; Garnett M; Mason C; Marais R
Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
[TBL] [Abstract][Full Text] [Related]
15. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
16. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
17. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
19. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]